MRFR is the Leading Brand in The Research Company who Recently Published Peripheral
Artery Disease Market Research Reports which includes Study of growth, Regional Analysis,
Top Industry Players Formation, Major Drivers, Upcoming Trends and Forecast to 2023.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/1540
Industry Leading Players
Boston Scientific Corporation, KONINKLIJKE PHILIPS N.V, Abbott, Medtronic, B. Braun
Melsungen AG, TERUMO CORPORATION, Becton, Dickinson and Company (BD), Sanofi S.A.,
Johnson & Johnson Services, Inc., AstraZeneca Plc., Angioscore, Inc., Bristol-Myers Squibb
Company, Betagenon AB, Proteon Therapeutics, Inc., Merck & Co., Inc., Bayer HealthCare
Pharmaceuticals, Symic Bio, Inc., CardioVascular BioTherapeutics, Inc., AnGes, Inc.,
TheraVasc Inc., Smith & Nephew plc, Stryker Corporation, Cook Medical, Cordis, Aspen
Surgical Products, Inc., Alcon Laboratories, Inc., Zimmer Biomet Holdings, Inc., and others
are some of the prominent players at the forefront of competition in the peripheral artery
disease market and are profiled in MRFR Analysis.
Peripheral Artery Disease Market - Overview
The peripheral artery disease market is growing mainly due to rising prevalence of arterial
diseases. According to a recent study report published by the Market Research Future, the
peripheral artery disease market is booming and expected to gain prominence over the
forecast period. The market is forecast to demonstrate a spectacular growth by 2023,
surpassing its previous growth records in terms of value with a striking CAGR during the
anticipated period (2017 – 2023).
Peripheral artery disease, also known as peripheral vascular diseases or peripheral Occlusive
diseases, is a narrowing of the peripheral arteries due to deposition of plaque or cholesterol
on the walls of artery. The most common symptoms of the disease includes painful
cramping in hip, thigh or calf muscles, coldness in lower leg or foot, Hair loss or slower hair
growth, no pulse or a weak pulse in legs or feet, sores on toes, feet or legs, and erectile
dysfunction in men. Peripheral artery disease is mostly caused by atherosclerosis in the
peripheral arteries. In atherosclerosis, plaque becomes brittle, and triggers clot formation
which further narrow the artery, or completely block it.
Notably, rising research and development expenditure is the primary driver for peripheral
artery disease market. In the year of 2016, the R&D expenditure in the Pharmaceutical
Industry was EUR 35000 million, suggested by European Federation of Pharmaceutical
Industries and Association. According to the Centres for Disease Control and Prevention, the
per capita national health expenditures in 2015 was amounted to be USD 9,990 and total
national health expenditure was USD 3.2 trillion. It is also reported that out of total national
health expenditures in the US, prescription drugs 10.1% share.
Other push factors such as, rising prevalence of arterial diseases, and related complications,
increasing awareness among the people, changing reimbursement policies, and growing
geriatric population are also fuelling the growth of the market. As per the Pacific Bridge
Medical, the government of China partially reimburses the cost of many drugs, provided the
drug is in the list of China’s National Reimbursement Drug List (NRDL) which was first
published in 2000. According to the Indian Brand Equity Foundation (IBEF), in 2016 the
generics market of India stood at USD 26.1 billion.
Despite these drivers, presence of misbranded and spurious drugs, risk of infections, and
side effects associated with treatment options are expected to hinder the growth of the
market.
Peripheral Artery Disease Market - Competitive Analysis
The peripheral artery disease market is currently dominated by various players. Due to
rising research and development expenditure various existing and new marketers are
continuously coming up with advanced drugs to control this condition. The global peripheral
artery disease market is currently dominated by numerous players.
Abbott is one of them by holding a strong share in the market. The company is a global
leader that develops and manufactures pharmaceuticals and medical products. In 2017, the